Sarepta Therapeutics (NASDAQ:SRPT) Receives Outperform Rating from Raymond James

Raymond James restated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT - Free Report) in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm currently has a $150.00 price target on the biotechnology company's stock.

A number of other research analysts have also commented on SRPT. Robert W. Baird lifted their price objective on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an outperform rating in a research note on Friday, June 21st. Leerink Partners boosted their price target on Sarepta Therapeutics from $165.00 to $230.00 and gave the company an outperform rating in a research report on Monday, June 24th. Piper Sandler decreased their price objective on Sarepta Therapeutics from $205.00 to $200.00 and set an overweight rating for the company in a research report on Thursday, August 8th. Cantor Fitzgerald reissued a neutral rating and issued a $152.00 target price on shares of Sarepta Therapeutics in a report on Friday, September 20th. Finally, William Blair raised Sarepta Therapeutics to a strong-buy rating in a report on Friday, August 30th. Two equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of Moderate Buy and a consensus price target of $185.47.

Sarepta Therapeutics Stock Up 3.7 %

SRPT traded up $4.42 on Thursday, reaching $122.41. The company's stock had a trading volume of 1,083,132 shares, compared to its average volume of 1,271,376. The stock has a 50 day moving average of $131.02 and a two-hundred day moving average of $132.55. Sarepta Therapeutics has a fifty-two week low of $55.25 and a fifty-two week high of $173.25. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $11.57 billion, a price-to-earnings ratio of 1,108.73 and a beta of 0.82.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The company had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm's revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.27) earnings per share. As a group, analysts forecast that Sarepta Therapeutics will post 1.45 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Ian Michael Estepan sold 5,985 shares of the business's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of the company's stock in a transaction dated Friday, August 16th. The shares were acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares of the company's stock, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the company's stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company's stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.70% of the company's stock.

Institutional Trading of Sarepta Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Farallon Capital Management LLC grew its position in Sarepta Therapeutics by 102.8% during the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company's stock worth $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Sarepta Therapeutics by 693.7% during the second quarter. Principal Financial Group Inc. now owns 363,011 shares of the biotechnology company's stock valued at $57,356,000 after purchasing an additional 317,277 shares during the period. Vanguard Group Inc. raised its stake in shares of Sarepta Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company's stock valued at $850,139,000 after purchasing an additional 243,180 shares in the last quarter. Canada Pension Plan Investment Board lifted its position in Sarepta Therapeutics by 2,257.8% in the first quarter. Canada Pension Plan Investment Board now owns 240,500 shares of the biotechnology company's stock worth $31,135,000 after purchasing an additional 230,300 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Sarepta Therapeutics by 5.6% during the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company's stock worth $398,025,000 after buying an additional 217,810 shares in the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.